Breast MRIs haven't been studied in the general population. So, what constitutes a woman at a high-risk for breast cancer, thus warranting the screening breast MRI?
"The only way to get into that [MRI screening] bracket is to have a significant family history of breast cancer," Russell says.
That means more than just having a relative with breast cancer. A woman would be considered at high risk ...
What will be the next discredited medical practice? Financial incentives is one reason why procedures are favored. However, don't forget about patient demand, the public who won't accept the evidence-based studies, and the media that perpetuates the myth that more testing is better medicine. (via OnThePharm)
Robert Centor thinks they've misinterpreted the study, showing again how economists shouldn't be an authority ...
Couples surgery is becoming the in thing for cosmetic procedures.
Dr. Gott perpetuates a common myth that nuts are to be avoided in patients with diverticulitis. There are no studies supporting this old wives' tale, yet many physicians continue to recommend this anyways.
With P4P on the horizon, over 80% of physicians feel this way:
"I have 10 to 15 patients whom I would have to fire," one respondent said. "The poor, unmotivated, obese and noncompliant would all have to find new physicians."
Panda Bear just finished a rotation with a micromanager. Every academic residency program as a couple of attendings who are completely out of touch with real-world medicine, making life difficult for the residents.
Only if Sepracor plays its cards right, according to OnThePharm:
In 2008, CFC inhalers are going away, a topic I've covered extensively here and here. That leaves Sepracor in a position to make themselves quite a lot of money if they're willing to do one thing out of the ordinary: price the Xopenex HFA MDI at or below the same price as the other HFA albuterol products. This would set ...
Not surprisingly, it seems like the Mike Zubillaga's remarks at AstraZeneca is simply par for the course at Big Pharma.
The mob is getting into prescription drugs:
'Counterfeit?' asked Tony.
'No,' says the sleazeball across the table, 'Old. You change the expiry date. Nobody knows.'
Paul Levy outlining some of the options dealing with the variability of end of life care:
As a person involved in policy-making in other arenas, I am left wondering what one would actually do with this information if you could "pass a law". If you were in the government, would you act to apportion hospital and physician resources across the country? Highly doubtful. Would you change the method of ...
Gina Kolata starts off a NY Times series discussing heart disease, and how many patients don't receive optimal treatment.
Inspired by Keith Richards' claim, Slate takes on this question.
One of the major reasons why standard of care practiced in the community differs from the courtroom.
Fallout from the Peter Rost-inspired firing. Pharmalot and Peter Rost's blog with more.
A handy page that many media members would benefit from. (via Medpundit)
The trial showed the benefits of the diabetes drug Byetta. The accompanying editorial is not kind.
Again, major media is dismissing evidence-based medicine with regards to cancer screening. We might as well give up and start practicing medicine based on anecdotes and expert opinion - since no one listens, nor accepts, the evidence. CNN correspondent Sanjay Gupta further damages the evidence-based movement with his bias during his show.
Maurice Bernstein writes about how making diagnoses are rarely black and white:
In fact, I think the art really trumps the science itself in most cases. Why do I say that? It is because no two patients are the same and no two same diseases present exactly the same way nor are their courses exactly the same. It is also because lab tests are rarely or ever 100% ...
That's what you get when bureaucrats run the show.
Much has been written about the drug seekers. How about patients who refuse to take Oxycontin because of the media exposure? (via White Coat Notes)